Alnylam Pharmace. buy Redburn Atlantic
Start price
31.03.25
/
50%
€249.70
Target price
31.03.26
€325.61
Performance (%)
3.64%
Price
15:04
€258.80
This prediction will end soon
Summary
This prediction is currently active. With a performance of 3.64%, the BUY prediction by Redburn_Atlantic for Alnylam Pharmace. is trending in the right direction. This prediction currently runs until 31.03.26. The prediction end date can be changed by Redburn_Atlantic at any time. Redburn_Atlantic has 50% into this predictionAlnylam Pharmaceuticals, Inc. (ALNY) is a biopharmaceutical company focused on the development of RNA interference (RNAi) therapeutics. Its lead drug, ONPATTRO®, is approved by the U.S. FDA for the treatment of adults with polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis. The company is also developing additional RNAi therapeutic candidates for the treatment of a range of diseases, including cancer, cardiovascular disease, and viral infections. With a market capitalization of over $15 billion, Alnylam is one of the largest biotech companies in the world.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Alnylam Pharmace. | -4.728% | -4.728% |
| iShares Core DAX® | -3,51 % | -8,75 % |
| iShares Nasdaq 100 | -2,78 % | -0,63 % |
| iShares Nikkei 225® | -2,04 % | -6,84 % |
| iShares S&P 500 | -2,60 % | -2,23 % |
Comments by Redburn_Atlantic for this prediction
In the thread Alnylam Pharmace. diskutieren
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Redburn Atlantic. They set a "buy" rating and a $353.00 price target on the stock.
Ratings data for ALNY provided by MarketBeat